SABOURETCardiologist Sergio Kaiser MD, PhD, FACC, FESC 🇧🇷🇮🇱🇷🇴🇺🇦 American Diabetes Association - DiabetesPro ❗️and the results❗️ 🔹non-inferiority of Tirzepatide to Dulaglutide 🔸Superiority thresholds NOT met 🔹Great all cause mortality separation

#LylasLaw 💛💝🌻 petition.parliament.uk/petitions/7286…

Really proud of Nicola Milne RN QN launching her book Oxford Handbook of Diabetes Nursing A must read!

📊 Meta-analysis of 10 GLP-1RA RCTs · ↓ MACE by 14% · ↓ HF hospitalisation + kidney outcomes 👉 Glycaemic control, not weight loss, associated with CV benefits of GLP-1RAs pubmed.ncbi.nlm.nih.gov/40926380/

10% of individuals use GLP-1ra Glucagon-Like Peptide-1 Agonists after Undergoing Bariatric Surgery in the US #Diabetes #obesity #bariatricsurgery @JAMA Surgery @JAMA Network jamanetwork.com/journals/jamas…

💡The first step in healthcare is self-care 🔥My latest Medscape Medical Mentor podcast is live! 🚨Improving cardiometabolic health in #T2D, focusing on the importance of 24-hour physical behaviours for people living with #T2D or the 5 𝗦's On Spotify & Apple Podcasts

Next week- we have Diabetes Professional Care in Olympia, London Looking forward to talking about progress made in #T1Diabetes; Access to #Technology; #T2D update re CGM - and of course-what comes next If there- come and say hello! And ask what you want 🙂 (Nearly) a decade in NHS England

The Yale Obesity Symposium A one-day 7 CME event November 21 2025 NEW developments in Obesity Treatment Speakers including: Lee Kaplan MD PhD Ania Jastreboff MD PhD John Morton MD Register NOW! cme.edu Yale University Yale School of Medicine Yale Surgery Obesity GLP-1ra

Some basics to remember!!! And it may help save a life Check for #T1Diabetes at the slightest suspicion Please cascade to colleagues and keep at improving awareness Thank you (Poster via Diabetes UK) #gbdoc 💙

💊 SGLT2 inhibitors & phimosis risk in men with T2D 📍 Danish cohort study (2016–2021) comparing SGLT2i vs GLP-1RA initiators 📊 1-year phimosis risk: 0.9% vs 0.5% → RR 1.88 (95% CI 1.43–2.47) 📊 8-year risk: 4.8% vs 3.6% → RR 1.36 (95% CI 1.14–1.61) ⚠️ Risk remains

As promised? Communication out to all outstanding 9/42 ICS re implementation of NG 28 NICE (published March 2022) via NHS England One of the last few things to hopefully close down before end March 2026 Prof Kamlesh Khunti samuel seidu Prof. Wasim Hanif Diabetes UK

🚨 NEW GUIDANCE for CGM use and class 2 drivers 🚗 ➡️CGM now safe to use if class 2 drivers ONLY IF approved for non adjunctive use!! ✅ Do use our CGM comparison chart to check which ones will be safe to use here: 🔗 diabetesspecialistnurseforumuk.co.uk/new-cgm-compar…

❗️A trial we have kept an eye on announces primary outcome met ❗️ FINE-ONE Finerenone in T1DM potentially provides an opportunity to address renal risk (maybe more) in this population with unmet need bayer.com/en/us/news-sto… Dr Amar Puttanna 🎸 Patrick Holmes Prof Kamlesh Khunti

A pleasure as ever to speak to GP colleagues and primary care Thank you PCDO Society for the invite Acknowledgement on behalf of NHS England of the amazing work all do- and the key to improving #Diabetes outcomes Twas fun 🥰 Prof Kamlesh Khunti samuel seidu

#GLP1 is forcing Big Food to finally reform. Not through regulation, but ⤵️💰 12% of US adults on GLP-1s = ⤵️8.6% in household food spending. 🔹Ultra-processed foods hit hardest 🔸 $12bn potential loss for junk food. Nestlé, General Mills, even Greggs scrambling to

Insight delivered. Expertise shared. The first sessions of #CVRMUK2025 tackled emerging evidence in cardio-renal medicine. Key takeaways already echo across disciplines: integration matters. Looking forward to exploring how these insights translate to everyday clinical decisions.

Welcome to Cardio-renal-metabolic UK London Autumn 2025!

Some personal reflections on the recent GMC workforce report- along with The BMJ investigation regards the 'gig economy' being run by #NHS Trusts. The system has no idea what to do next- apart from warm words and a lot of hand wringing- especially with the situation

💪🏾Mind the Muscle: Incretin Therapies for Weight Loss💪🏾 🔥The hottest of topics with incretin therapies🔥 Here's my last Medscape perspective piece from The Obesity Society ObesityWeek® congress in Atlanta - link in comments 👇🏾

#GLP1's & erectile function: friend or foe? 🔬 New Biomolecules review: mostly friend❗️ ✅ Improve endothelial function ✅ Boost testosterone via weight loss ✅ REWIND: dulaglutide cut ED risk (HR 0.92) Responses vary - ask at follow-up. 🔗mdpi.com/2218-273X/15/9…